Pipeline

A pipeline of neuroprotectants for multiple indications, Avilex’ lead compound, AVLX-144, is entering Phase 2 clinical trials, and a range of new preclinical assets are being developed

Compound(s)

Lead Optimization

Non-Clinical

Regulatory Toxicology

Phase I

Phase II

Phase III

AVLX-144

Carefully optimized, unique structure

Extensively characterized in stroke in vivo models

Completed full toxicology package

Completes clinical trial Phase I

2nd GenerationPSD-95 Inhibitors

New potent inhibitors with unique properties

In vivo characterization ongoing

PSD-95 PET TracerClinical Biomarker Studies

Highly promising PSD-95 biomarker developed

In vivo characterization ongoing

Cyclic PeptidePSD-95 Inhibitors

Novel, potent cyclic peptide inihibtors developed

AVLX-144

Lead Optimization

Carefully optimized, unique structure

Non-Clinical

Extensively characterized in stroke in vivo models

Regulatory Toxicology

Completed full toxicology package

Phase I

Completes clinical trial Phase I

Phase II

Phase III

2nd Generation

PSD-95 Inhibitors

Lead Optimization

New potent inhibitors with unique properties

Non-Clinical

In vivo characterization ongoing

Regulatory Toxicology

Phase I

Phase II

Phase III

PSD-95 PET Tracer

Clinical Biomarker Studies

Lead Optimization

Highly promising PSD-95 biomarker developed

Non-Clinical

Extensively characterized in stroke in vivo models

Regulatory Toxicology

Phase I

Phase II

Phase III

Cyclic Peptide

PSD-95 Inhibitors

Lead Optimization

Highly promising PSD-95 biomarker developed

Non-Clinical

Regulatory Toxicology

Phase I

Phase II

Phase III

Last update

21 Nov - 2020

Successfully completes phase 1 clinical trial

Avilex Pharma successfully completes its phase 1 clinical trial of AVLX-144 – A potentially game-changing treatment for acute neurological conditions

Avilex Pharma, a clinical stage biotechnology company developing innovative treatments for acute neurological conditions such as acute ischemic stroke (AIS) and subarachnoid haemorrhage (SAH), is excited to announce the successful completion of the company’s first-in-human Phase 1 clinical trial of its lead compound AVLX-144. During the course of the Phase I study, AVLX-144 was well-tolerated and demonstrated no noteworthy safety issues related to treatment  The result provides a solid foundation for Avilex’s transition into later phase clinical trials to further study the compound’s efficacy.

Get in touch